Cefiza-DX Tablet
Cefixime 200 mg + Dicloxacillin 500 mg Sustained Release Tablets
| Composition | Cefixime 200 mg + Dicloxacillin 500 mg (Sustained Release) |
|---|---|
| Dosage Form | Sustained Release Tablet |
| Pack Type | Alu-Alu Blister |
| Pack Size | 10 x 10 Tablets |
| MRP | ₹ 3200 |
| Therapy | Antibiotic + G.P. + Orthopaedics — Cephalosporin + Penicillinase-Resistant Penicillin |
| Storage | Store below 30 °C in a dry place, protected from light and moisture. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Cefiza-DX Tablet
Cefiza-DX Tablet combines Cefixime 200 mg with Dicloxacillin 500 mg in a sustained-release format. The combination is used for mixed gram-positive and gram-negative skin/soft-tissue infections — particularly diabetic foot infections, post-surgical wound infections and severe cellulitis where both staphylococcal and gram-negative coverage is needed empirically.
Dicloxacillin is a penicillinase-resistant penicillin specifically active against methicillin-sensitive Staphylococcus aureus (MSSA). Combined with cefixime’s broad gram-negative coverage, this dual therapy provides comprehensive empirical coverage for mixed-flora skin and soft-tissue infections.
Cefiza-DX is manufactured by Trumac Healthcare under WHO-GMP conditions. Available for monopoly-based PCD pharma franchise and third-party manufacturing — a high-value antibiotic SKU.
Indications
- Mixed-flora skin and soft-tissue infections
- Diabetic foot infections
- Post-surgical wound infections
- Severe cellulitis with mixed flora suspected
- Bone and joint infections (adjunct)
Mechanism of Action
Cefixime binds penicillin-binding proteins (PBP-3) on gram-negative bacteria, inhibiting the final transpeptidation step of peptidoglycan synthesis. The result is bacterial cell wall destabilisation and osmotic lysis. Cefixime is resistant to many beta-lactamases produced by gram-negative organisms — distinguishing it from earlier cephalosporins. Dicloxacillin's bulky isoxazolyl side chain sterically prevents beta-lactamase hydrolysis, retaining activity against penicillinase-producing MSSA.
Dosage & Administration
Adults: 1 tablet twice daily for 7–14 days depending on infection severity. SR matrix releases drug over 12 hours.
Side Effects
GI upset, nausea, diarrhoea, mild rash. Rare: hypersensitivity, pseudomembranous colitis, hepatic enzyme elevation.
Contraindications & Precautions
Hypersensitivity to cephalosporins. Severe penicillin allergy (cross-reactivity ~10%). Renal impairment requires dose adjustment. History of GI disease (caution). Severe penicillin allergy. Infectious mononucleosis (Dicloxacillin rash risk).
Storage
Store below 30 °C in a dry place, protected from light and moisture.
Cefiza-DX Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Cefiza-DX used for?
Cefiza-DX contains Cefixime 200 mg + Dicloxacillin 500 mg SR and is used for bacterial infections — UTI, ENT, respiratory tract, gastrointestinal and gynaecological infections in the appropriate age group.
How long is the course?
Typical course is 5–7 days; longer in complicated infections. Always complete the prescribed course to prevent resistance.
Is Cefiza-DX available for PCD pharma franchise?
Yes, Trumac Healthcare offers Cefiza-DX on monopoly-based PCD pharma franchise and for third-party manufacturing.
How should Cefiza-DX be stored?
Store below 30 °C in a dry place, protected from light and moisture.
Is Cefiza-DX WHO-GMP certified?
Yes, manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Cefiza-200 DT Tablet — Cefixime Trihydrate 200 mg (Dispersible)
- Camdiclox-LB Capsule — Amoxicillin 250 mg + Cloxacillin 250 mg + Lactobacillus 2 Billion Spores
- Cefiza-CV Tablet — Cefixime Trihydrate 200 mg + Clavulanic Acid 125 mg